CMPX

Compass Therapeutics, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website compasstherapeutics.com
Employees(FY) 26
ISIN US20454B1044

Performance

-8.61%

-2.82%

-20.23%

+23.21%

-11.54%

YTD

-13.21%

Profile

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. Compass Therapeutics, Inc. was founded in 2014 and is headquartered in Boston, Massachusetts.

Advanced Technical Analysis

Technical Analysis of CMPX 2024-12-20

The stock indicators reflect a bearish sentiment overall, with a Moving Average Score of 10 indicating strong downward momentum, an Oscillators Score of 46 suggesting a neutral stance, and a Technical Score of 28 reinforcing the bearish outlook. This combination signals caution for potential investors, as the prevailing trend appears to be negat...

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of CMPX

Stock Rank

Recent News & Updates

2024-12-09 19:00
Compass Therapeutics Appoints Biopharmaceutical Industry Leader Barry Shin as Chief Financial Officer(Globenewswire)
2024-12-01 19:00
Compass Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference(Globenewswire)
2024-11-12 19:30
Compass Therapeutics to Participate in Upcoming Investor Events(Globenewswire)
2024-11-11 19:00
Compass Therapeutics Reports 2024 Third Quarter Financial Results and Provides Corporate Update(Globenewswire)
2024-11-07 21:05
Compass Therapeutics Presents Novel Biomarker Data Related to CTX-471 Clinical Activity at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting(Globenewswire)
2024-10-03 22:31
Compass Therapeutics Announces Upcoming Poster Presentation at the 39th Society for Immunotherapy of Cancer Annual Meeting(Globenewswire)
2024-09-02 20:00
Compass Therapeutics to Participate in Upcoming Investor Events(Globenewswire)
2024-08-11 20:00
Compass Therapeutics Reports 2024 Second Quarter Financial Results and Provides Corporate Update(Globenewswire)
2024-08-06 20:00
Compass Therapeutics to Participate in the Wedbush PacGrow Healthcare Conference(Globenewswire)
2024-08-05 20:00
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer(Globenewswire)
2024-07-10 00:00
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why(Zacks)
2024-05-29 20:00
Compass Therapeutics to Participate in the Jefferies Global Healthcare Conference(Globenewswire)
2024-05-28 04:10
Compass Therapeutics Announces CEO Transition(Globenewswire)
2024-05-23 05:05
Compass Therapeutics to Present Phase 1 Data for CTX-471, A Novel CD137 Agonist Antibody, Demonstrating Anti-Tumor Activity in Patients Who Have Progressed on Approved PD-1 or PD-L1 Inhibitors at the American Society of Clinical Oncology (ASCO) Annual Meet(Globenewswire)
2024-05-13 20:00
Compass Therapeutics to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference(Globenewswire)
2024-05-13 02:53
CMPX Stock Earnings: Compass Therapeutics Beats EPS for Q1 2024(Investorplace)
2024-05-12 20:00
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update(Globenewswire)
2024-04-24 20:00
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated(Yahoo Finance)
2024-04-15 20:00
Compass Therapeutics Announces First Patient Dosed in the Phase 1 Study of CTX-8371 in Patients with Solid Tumors(Globenewswire)
2024-04-11 20:00
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference(Globenewswire)
2024-04-09 20:00
Compass Therapeutics to Participate in the Stifel Targeted Oncology Days(Globenewswire)
2024-04-09 00:00
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting(Globenewswire)
2024-03-21 10:54
CMPX Stock Earnings: Compass Therapeutics Misses EPS for Q4 2023(Investorplace)
2024-03-20 21:00
Compass Therapeutics Reports 2023 Financial Results and Provides Corporate Update(Globenewswire)
2024-02-28 19:00
Compass Therapeutics to Participate in the Leerink Partners Global Biopharma Conference(Globenewswire)
2024-02-27 19:00
Compass Therapeutics Announces Publication of CTX-8371 Preclinical Data in OncoImmunology, its Bispecific Antibody Checkpoint Inhibitor, now Advancing to First-in-Human Clinical Trial(Globenewswire)
2024-02-07 23:00
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's What You Should Know(Zacks)
2024-01-04 19:00
Compass Therapeutics Provides Corporate Update(Globenewswire)
2023-11-08 19:17
Compass Therapeutics Inc (CMPX) Reports Q3 2023 Financial Results and Corporate Developments(Yahoo Finance)
2023-11-08 18:30
Compass Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update(Globenewswire)

Page 1 of 3

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.